Evoke Pharma Inc (EVOK) Return on Assets ROA from the third quarter of 2025 to third quarter of 2024 and for the year 2025, Average High and Low, Fundamental Ratios from Sep 30 2025 to Sep 30 2024 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Evoke Pharma Inc   (NASDAQ: EVOK)


Evoke Pharma Inc 's ROA from the third quarter of 2025 to the third quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Evoke Pharma Inc 's ROA in the third quarter of 2025?
Evoke Pharma Inc recorded a cumulative net loss of $-5 million during 12 months ending in the third quarter of 2025, resulting in a negative return on assets (ROA) of -31.86%.

However, within the Healthcare sector 462 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Sep 30 2025 quarter, so far to 3805, from total ROA ranking in the second quarter of 2025 at 3844.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter		 (Dec 31 2024)
IV. Quarter		 (Sep 30 2024)
III. Quarter
Y / Y Total Assets Change 10.57 % 32.33 % 31.49 % -51.35 % 80.23 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -5 -5 -5 -5 -6
Return On Assets (TTM) -31.86 % -33.58 % -33.75 % -38.05 % -32.89 %
EVOK's Total Ranking # 3805 # 3844 # 3913 # 4624 # 4297
Total Assets (TTM) in million 16 16 16 18 14
Seq. Total Assets Change -2.56 % -1.93 % -6.52 % 23.78 % 16.62 %
Seq. Net Income Change - - - - -

EVOK's 5 Years Annual ROA >> Back to EVOK Management Effectiveness >> Compare EVOK ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 187
Sector # 463
Overall # 3759

Return On Assets Statistics
High Average Low
108.32 %
-85.69 %
-188.93 %
(Mar 31 2014)   (Sep 30 2020)



  News about Evoke Pharma Inc Return on Assets ROA

Evoke Pharmas Strategic Moves: Pioneering Gastroparesis Solutions Amid Market Transitions and Shareholder Enhancements

In the ever-evolving landscape of pharmaceutical innovation, Evoke Pharma, Inc. (NASDAQ: EVOK) is carving out a significant niche as a leading provider of treatments for gastrointestinal (GI) disorders, particularly in the realm of gastroparesis. With their flagship product, GIMOTI (metoclopramide) nasal spray, gaining attention as a compelling alternative amidst shifting dynamics in the market, the company is positioning itself to address the growing needs of patients and stakeholders alike. This month, Evoke Pharma made



Financial Statements
Evoke Pharma Inc 's Assets $ 16 million EVOK's Balance sheet
Evoke Pharma Inc 's Income $ -1 million Quarterly EVOK's Income Statement
EVOK's Income by Division See EVOK's Income by Division



Annual Return On Assets (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020
Y / Y Total Assets Change 147.84 % -40.36 % 12.09 % 12.07 % 47.51 %
Total Assets in million 18 7 12 11 9
Y / Y Net Income Change - - - - -
Net Income in million -5 -8 -8 -9 -13
Annual Return On Assets -30.55 % -110.24 % -69.39 % -80.75 % -139.44 %

EVOK's 5 Years Annual ROA >> Back to EVOK Management Effectiveness >> Compare EVOK ROA to its Competitors



More Return On Assets Ratios
EVOK's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
EVOK's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for EVOK's Competitors
Subscribers only: Roa for Evoke Pharma Inc 's Suppliers
Subscribers only: Return On Assets for EVOK's Customers

You may also want to know
EVOK's Roi EVOK's Inventory Turnover Ratio EVOK's Growth Rates EVOK's Dividend Comparisons
EVOK's Profitability Ratios EVOK's Asset Turnover Ratio EVOK's Dividend Growth
EVOK's Roe EVOK's Valuation Ratios EVOK's Financial Strength Ratios EVOK's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2025, within Healthcare Sector ROA

Date modified: 2026-09-26T07:01:42+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.